TBPMF News and Press, Tetra Bio-Pharma Inc From 04/16/20

Tetra's PPP004 cannabinoid drug receives Orphan Drug Designation for the Treatment of Epidermolysis Bullosa OTTAWA / ACCESSWIRE / April 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP);(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is...

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative Vitreoretinopathy OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and de...

DEA Renews Schedule 1 License for Scottsdale Research Institute (Plenitude clinical site) OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to anno...

Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions Canada NewsWire OTTAWA, April 8, 2020 TETRA BIO-PHARMA VOLUNTEERS TO GUIDE MEDICAL DEVICE/ HEALTH-RELATED MANUFACTURERS OTTAWA , April 8, 2020 /CNW/ - Tetra B...

OTTAWA, April 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("...

Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra &#...

Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities Canada NewsWire OTTAWA, April 1, 2020 /NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/ OTTAWA , April 1, 2020 /CNW Telbec/ - Te...

OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Corporation ") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 (" Restated MD&...

OTTAWA, March 26, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian pa...

OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would like to announce that it has ensured that all of its employees...